Antibodies as Drugs: The Art in Antibody Engineering
May 5-8, 2024 | Beaver Run Conference Center, Breckenridge, CO, United States
Scientific Organizers:
Laura M. Walker and Paul W. H. I. Parren
In Person
On Demand
May 5-8, 2024 | Beaver Run Conference Center, Breckenridge, CO, United States
Scientific Organizers:
Laura M. Walker and Paul W. H. I. Parren
Available Formats:
In Person
On Demand
Supported by the Directors' Fund
Available Formats: = In Person = On Demand
Merchandise Options
Registration Options
Booking Function
Fundraising
Sunday, May 5, 2024
Arrival and Registration
4:00–8:00 PM
Colorado Ballroom Foyer
Welcome Mixer
6:00–8:00 PM
Colorado Ballroom Foyer
Monday, May 6, 2024
Breakfast
7:00–8:00 AM
Summit Gallery
Welcome and Keynote Address
8:00–9:00 AM
Peaks 4 - 5
* Laura M. Walker, Moderna
Session Chair
Session Chair
* Paul W. H. I. Parren, Leiden University Medical Center
Session Chair
Session Chair
Janine Schuurman, Lust for Life Science
Mining Antibody Biology for Novel Functionalities and Therapeutic Antibody Development
Mining Antibody Biology for Novel Functionalities and Therapeutic Antibody Development
Fine-Tuning Antibody Fc Function
9:00–11:15 AM
Peaks 4 - 5
* CM Hsieh, Gilead Sciences
Session Chair
Session Chair
E. Sally Ward, University of Southampton
The Science of FcRn: Tuning Antibody and Antigen Degradation
The Science of FcRn: Tuning Antibody and Antigen Degradation
John R. Desjarlais, Xencor, Inc.
Engineering Therapeutic Antibodies to Optimize Half-Life and Function
Engineering Therapeutic Antibodies to Optimize Half-Life and Function
Jeanette H.W. Leusen, University Medical Center Utrecht
Engineered IgA Antibody Therapeutics
Engineered IgA Antibody Therapeutics
Remy M Muts, UMC Utrecht
Short Talk: Conversion of S. Aureus Specific IgG Into IgM Broadens the Reactivity to Other Bacterial Species
Short Talk: Conversion of S. Aureus Specific IgG Into IgM Broadens the Reactivity to Other Bacterial Species
Coffee Break
9:30–9:50 AM
Colorado Ballroom Foyer
On Own for Lunch
11:15–5:00 PM
Poster Setup
11:15–1:00 PM
Peaks 1 - 3
Poster Viewing
1:00–10:00 PM
Peaks 1 - 3
Career Roundtable
3:00–4:30 PM
Peaks 4 - 5
Kartik Chandran, Albert Einstein College of Medicine
Professor and Chair
Professor and Chair
Joy Yu Zuchero, Denali Therapeutics Inc
Director and Principal Scientist
Director and Principal Scientist
Jeanette H.W. Leusen, University Medical Center Utrecht
Professor
Professor
George Voren, Curie.Bio
Head of Founder Strategy and Operations
Head of Founder Strategy and Operations
Coffee Available
4:30–5:00 PM
Colorado Ballroom Foyer
Engineered Antibodies in Infectious Disease
5:00–7:00 PM
Peaks 4 - 5
* Jacqueline Kirchner, Bill & Melinda Gates Foundation
Session Chair
Session Chair
Kartik Chandran, Albert Einstein College of Medicine
Engineered Antibodies for Treating Emerging Viral Infections
Engineered Antibodies for Treating Emerging Viral Infections
Gary J. Nabel, ModeX Therapeutics
Multispecific Immunotherapies for Infectious Disease
Multispecific Immunotherapies for Infectious Disease
Galit Alter, Moderna, Inc.
Unraveling Correlates of Immunity with Systems Serology in Drug Development and Vaccines
Unraveling Correlates of Immunity with Systems Serology in Drug Development and Vaccines
Michael P Doyle, AstraZeneca
Short Talk: Broad Coverage of Antibiotic-Resistant Klebsiella Pneumoniae by Multi-Specific Antibodies Against the Lipopolysaccharide O-Antigen
Short Talk: Broad Coverage of Antibiotic-Resistant Klebsiella Pneumoniae by Multi-Specific Antibodies Against the Lipopolysaccharide O-Antigen
Jiaxuan Cheng, Vaccine Research Center, NIAID/NIH
Short Talk: Structural Insights into Multimeric Recognition by Glycan-Directed Broadly Neutralizing Antibodies Targeting HIV-1 Envelope Glycoprotein
Short Talk: Structural Insights into Multimeric Recognition by Glycan-Directed Broadly Neutralizing Antibodies Targeting HIV-1 Envelope Glycoprotein
Social Hour with Lite Bites
7:00–8:00 PM
Peaks 1 - 3
Poster Session 1
7:30–10:00 PM
Peaks 1 - 3
Tuesday, May 7, 2024
Breakfast
7:00–8:00 AM
Summit Gallery
Orchestrating Immune Defense Against Cancer by Antibody Engineering
8:00–11:00 AM
Peaks 4 - 5
* Diane Hollenbaugh, Bonum Therapeutics, Inc.
Session Chair
Session Chair
Hans van der Vliet, Lava Therapeutics
Bispecific Antibodies for Recruiting Alternative Immune Cells for Cancer Therapy
Bispecific Antibodies for Recruiting Alternative Immune Cells for Cancer Therapy
Jamie Spangler, Johns Hopkins University
Engineering Antibodies and Fusion Proteins for Disease Targeting
Engineering Antibodies and Fusion Proteins for Disease Targeting
Stephen A. Beers, University of Southampton
Interplay Between the Tumor Microenvironment and the Antibody Fc in Optimizing Therapy
Interplay Between the Tumor Microenvironment and the Antibody Fc in Optimizing Therapy
Mika Kamata-Sakurai, Chugai Pharmaceutical
Conditional Activation of Protein Therapeutics in the Tumor Microenvironment’
Conditional Activation of Protein Therapeutics in the Tumor Microenvironment’
Pratik Bhojnagarwala, The Wistar Institute
Short Talk: Customized Ovarian Cancer Therapy Using in vivo Assembled Bi-Specific Antibodies Targeting Her2 and FSHR
Short Talk: Customized Ovarian Cancer Therapy Using in vivo Assembled Bi-Specific Antibodies Targeting Her2 and FSHR
John T Mulligan, Bonum Therapeutics, Inc.
Short Talk: A Novel Method for Generating Regulated Cytokine Therapeutics: Safety and Activity of a Conditionally Active cLAG3-IL2 in a Simple Antibody Format
Short Talk: A Novel Method for Generating Regulated Cytokine Therapeutics: Safety and Activity of a Conditionally Active cLAG3-IL2 in a Simple Antibody Format
Coffee Break
9:00–9:20 AM
Colorado Ballroom Foyer
On Own for Lunch
11:00–5:00 PM
Poster Setup
11:00–1:00 PM
Peaks 1 - 3
Poster Viewing
1:00–10:00 PM
Peaks 1 - 3
Workshop: Computational Antibody Engineering
2:30–4:30 PM
Peak 4-5
* Peter Tessier, University of Michigan
Session Chair
Session Chair
* Peter Tessier, University of Michigan
Predicting Antibody Developability using Interpretable Machine Learning
Predicting Antibody Developability using Interpretable Machine Learning
Fabian C Spoendlin, University of Oxford
Improved Computational Epitope Profiling Using Structural Models Identifies a Broader Diversity of Antibodies that Bind to the Same Epitope
Improved Computational Epitope Profiling Using Structural Models Identifies a Broader Diversity of Antibodies that Bind to the Same Epitope
Tobias Hegelund Olsen, GSK
Addressing the Antibody Germline Bias and its Effect on Language Models for Improved Antibody Design
Addressing the Antibody Germline Bias and its Effect on Language Models for Improved Antibody Design
Benjamin Rubin, Adaptive Biotechnologies
Multi-Modal, Broadly Neutralizing Antibodies to SARS-CoV-2 and Influenza Discovered via High-Throughput Native Pairing of BCRs From Bulk B Cells
Multi-Modal, Broadly Neutralizing Antibodies to SARS-CoV-2 and Influenza Discovered via High-Throughput Native Pairing of BCRs From Bulk B Cells
Brett Blakeley, Generate Biomedicines
Industrializing Therapeutic Antibody Design. Generative AI Enables Intentional Antibody Engineering Over Random Chance Discovery
Industrializing Therapeutic Antibody Design. Generative AI Enables Intentional Antibody Engineering Over Random Chance Discovery
Ira Zaretsky, Weizmann Institute of Science
From Mice to Men: Energy-Based Antibody Humanization
From Mice to Men: Energy-Based Antibody Humanization
Mark Hutchinson, AstraZeneca
Computational Optimization of an Anti-HEL Antibody Leads to Increased Antibody Thermostability and Affinity
Computational Optimization of an Anti-HEL Antibody Leads to Increased Antibody Thermostability and Affinity
Fernando Luis Barroso da Silva, University of Sao Paulo
Computational Insights and New Strategies for Advanced Antibody Engineering
Computational Insights and New Strategies for Advanced Antibody Engineering
Coffee Available
4:30–5:00 PM
Colorado Ballroom Foyer
Avidity Engineering and Antibody Cocktails
5:00–7:15 PM
Peaks 4 - 5
* Ellen Wagner, GigaGen
Session Chair
Session Chair
Paul W. H. I. Parren, Leiden University Medical Center
Avidity Engineering of Therapeutic Antibodies
Avidity Engineering of Therapeutic Antibodies
Bruce Keyt, IGM Biosciences
Multipecific, IgM-based, T Cell Engagers for Treating Cancer
Multipecific, IgM-based, T Cell Engagers for Treating Cancer
Jean-Philippe Julien, Hospital for Sick Children Research Institute
Avid and Multispecific Biologics for Global Health
Avid and Multispecific Biologics for Global Health
Ira Mellman, Genentech, Inc.
Rational Design of Combinatorial Targeting to Optimize Checkpoint Blockade
Rational Design of Combinatorial Targeting to Optimize Checkpoint Blockade
Alexandra Margaret Terry, Genmab
Short Talk: Exploring Interaction Rules for Multispecific Targeting using the HexElect Antibody Format
Short Talk: Exploring Interaction Rules for Multispecific Targeting using the HexElect Antibody Format
Social Hour with Lite Bites
7:15–8:15 PM
Peaks 1 - 3
Poster Session 2
7:30–10:00 PM
Peaks 1 - 3
Wednesday, May 8, 2024
Breakfast
7:00–8:00 AM
Summit Gallery
Engineered Antibody Constructs in the Clinic
8:00–11:00 AM
Peaks 4 - 5
* Jonathan Davis, Creative Antibodies
Session Chair
Session Chair
Koustubh Ranade, Immunocore
Advances Beyond Monoclonal Antibodies
Advances Beyond Monoclonal Antibodies
Laura M. Walker, Moderna
Prophylaxis and Treatment of Infectious Disease with Half-Life Extended Neutralizing Antibodies
Prophylaxis and Treatment of Infectious Disease with Half-Life Extended Neutralizing Antibodies
David P. Humphreys, UCB Pharma
TRYBE: An Fc-Free Antibody Format with Three Monovalent Targeting Arms and Engineered for Long in vivo Half-Life
TRYBE: An Fc-Free Antibody Format with Three Monovalent Targeting Arms and Engineered for Long in vivo Half-Life
Jaileene Hernandez Escalante, Generate Biomedicines
Short Talk: Development of a Machine Learning (ML) Designed Anti-TSLP Antibody for the Treatment of Asthma
Short Talk: Development of a Machine Learning (ML) Designed Anti-TSLP Antibody for the Treatment of Asthma
Mark Kroenke, Amgen
Short Talk: Translatability of Findings from Cynomolgus Monkey to Human Suggests a Mechanistic Role for IL-21 in Promoting Immunogenicity to an Anti-PD-1/IL-21 Mutein Fusion Protein
Short Talk: Translatability of Findings from Cynomolgus Monkey to Human Suggests a Mechanistic Role for IL-21 in Promoting Immunogenicity to an Anti-PD-1/IL-21 Mutein Fusion Protein
Coffee Break
9:00–9:20 AM
Colorado Ballroom Foyer
On Own for Lunch
11:00–5:00 PM
Coffee Available
4:30–5:00 PM
Colorado Ballroom Foyer
Fast Forward: Promising New Technologies and Applications
5:00–6:45 PM
Peaks 4 - 5
* Anna Park, Sanofi
Session Chair
Session Chair
Sai T. Reddy, ETH Zurich
Rational Design of Antibody Therapeutics via Deep Learning
Rational Design of Antibody Therapeutics via Deep Learning
Joy Yu Zuchero, Denali Therapeutics Inc
Brain Delivery of Therapeutic Proteins with Fc-Engineered Molecules
Brain Delivery of Therapeutic Proteins with Fc-Engineered Molecules
Garrett Rappazzo, Adimab LLC
Short Talk: Rapid Engineering of Soluble T Cell Receptors for Enhanced Affinity via a High-Throughput Yeast-Based Platform
Short Talk: Rapid Engineering of Soluble T Cell Receptors for Enhanced Affinity via a High-Throughput Yeast-Based Platform
Fangzhu Zhao, University of California San Francisco
Short Talk: Cytokine Receptor-Targeting Chimeras: Unveiling Dual Modalities for Targeted Protein Degradation and Immune Cell Engagement
Short Talk: Cytokine Receptor-Targeting Chimeras: Unveiling Dual Modalities for Targeted Protein Degradation and Immune Cell Engagement
Meeting Wrap-Up: Outcomes and Future Directions (Organizers)
6:45–7:00 PM
Peaks 4 - 5
Social Hour with Lite Bites
7:00–8:00 PM
Peaks 1 - 3
Trivia
8:00–9:00 PM
Peaks 4-5
Cash Bar
8:00–9:00 PM
Peaks 1 - 3
Thursday, May 9, 2024
Departure
7:00–11:59 PM
Subscribe for Updates